Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 4:08 AM
Ignite Modification Date:
2025-12-25 @ 4:08 AM
NCT ID:
NCT05884320
Brief Summary:
To learn if sacituzumab govitecan can help to control salivary gland cancer.
Detailed Description:
Primary Objectives:
* To assess the efficacy of SG in patients with R/M secretory gland carcinomas, specifically ACC (cohort 1) and SDC, adeno-NOS, and MEC (cohort 2)
Secondary Objectives:
* To estimate the median duration of response (DOR)
* To estimate the median progression-free survival (PFS)
* To estimate the median overall survival (OS)
* To assess safety of SG
Tertiary / Exploratory Objectives:
* To explore biomarkers that may predict response to therapy
Study:
NCT05884320
Study Brief:
Protocol Section:
NCT05884320